$0.867
-0.356 (-41.01%)Zum Schluss
CVRX-News
CVRX-Events
CVRx Reports Q3 Revenue of $12M, Below Consensus
Reports Q3 revenue $12M, consensus $13.91M. "While we recognize there is more work ahead, we remain encouraged by the progress we are making on key strategic initiatives, including the expansion of Medicare Advantage coverage and the clinical evidence released at HFSA," said Kevin Hykes, President and Chief Executive Officer of CVRx. "With new Medicare Advantage coverage policies, BENEFIT-HF enrolling, and continued focus on commercial execution, we are confident in our ability to bring this therapy to more patients living with heart failure."
Company Expects Q4 2026 Revenue Between $11.7M and $12.7M
The company said, "For the fourth quarter of 2026, the Company expects to report total revenue between $11.7 million and $12.7 million."
Sees FY26 Gross Margin at 86%-87%
Sees FY26 gross margin 86%-87%.
CVRx Appoints John Landry as CFO
CVRx announced that John Landry has been appointed CFO, succeeding Jared Oasheim, whose resignation was previously announced. Landry will join the company on October 12, and assume the CFO role on the day after the company files its Form 10-Q for the quarter ending September 30. Oasheim will remain with the company for a transition period consistent with his previously disclosed transition agreement.
CVRx Announces Devoted Health Coverage for Barostim Therapy
CVRx announced that Devoted Health has issued a Medicare Advantage coverage policy for Barostim therapy, effective July 17. Devoted Health, a national health insurance company with the eighth largest Medicare Advantage enrollment in the U.S., provides coverage to approximately 466,000 Medicare Advantage members across 29 states. The new policy covers Barostim for patients meeting its current FDA-approved indication as well as patients enrolled in the BENEFIT-HF trial, the landmark heart failure study evaluating Barostim in a significantly expanded patient population initiated earlier this year.
Ähnliche Artikel
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.